GoodRx: Flat Revenue Trends
GoodRx (GDRX +1.79%) primarily generates revenue by offering a price comparison tool that helps consumers find geographically relevant pricing and access negotiated discounts on prescription drugs across the United States.
While expanding its offerings to include new weight-loss medications and navigating a rejected privacy settlement in federal court, it reported about 21% EBIT margin for the quarter ended Dec. 31, 2025.
Hims & Hers Health: Sequential Revenue Growth
Hims & Hers Health (HIMS 1.62%) earns its revenue by operating a telehealth network that connects consumers to licensed healthcare professionals, providing medical consultations and ongoing prescription medication subscriptions directly to customers.
It shifted its strategy to collaborate with a major pharmaceutical manufacturer and faced several shareholder investigations, while generating approximately 72% gross margin for the quarter ended Dec. 31, 2025.
Why Revenue Matters for Retail Investors
Revenue here refers to the data provider's standardized income-statement revenue line item, and it serves as a straightforward indicator of overall consumer demand that helps investors evaluate whether a business is successfully attracting and retaining users.
Quarterly Revenue for GoodRx and Hims & Hers Health
| Quarter (Period End) | GoodRx Revenue | Hims & Hers Health Revenue |
|---|---|---|
| Q1 2024 (March 2024) | $197.9 million | $278.2 million |
| Q2 2024 (June 2024) | $200.6 million | $315.6 million |
| Q3 2024 (Sept. 2024) | $195.3 million | $401.6 million |
| Q4 2024 (Dec. 2024) | $198.6 million | $481.1 million |
| Q1 2025 (March 2025) | $203.0 million | $586.0 million |
| Q2 2025 (June 2025) | $203.1 million | $544.8 million |
| Q3 2025 (Sept. 2025) | $196.0 million | $599.0 million |
| Q4 2025 (Dec. 2025) | $194.8 million | $617.8 million |
Data source: Company filings.
Foolish Take
The top-line stagnation that has been frustrating GoodRX investors did not improve during the first three months of 2026. On May 6, the medication savings platform reported first-quarter sales that declined by 4.4% year over year to $194 million.
Revenue dropped, but GoodRx’s pharma direct business is encouraging investors. The stock rose more than 10% following its first-quarter report. Shareholders seem pleased with an 82% year-to-year gain for the company’s Pharma Direct business. At $52 million, the Pharma Direct business is responsible for about 27% of total revenue.
With the average annual cost for a family health plan reaching $27,000 in 2026, fewer Americans have access to a primary care physician. The rising cost of traditional access to prescription drugs has been a strong tailwind for Hims & Hers Health’s alternative platform.
His & Hers will announce first-quarter results on May 11, 2026. In the fourth quarter of 2025, the company reported 13% year over year subscriber growth. With fourth-quarter revenue that surged 59% year over year, it’s clearly outperforming GoodRx.
